Interestingly, a high baseline level of FoxP3+ Tregs within a tumor does not necessarily predict poor outcomes.98,123 In some cases, these Tregs co-exist with active immune responses, and their presence has been associated with improved clinical outcomes following anti-CTLA-4 therapy.123 Ongoing research is focused on fully understanding the role of Tregs and their impact on the efficacy of immunotherapies in different cancer settings. The gene discussed is CTLA4; the disease is neoplasm.